NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry.

Multi-dose vials will be launched at MRP of Rs 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of Rs 1,750 for 8mg/3ml, said ...

Natco Pharma has launched the Semaglutide injection in India on the first day of its patent expiry. Hyderabad-based Natco ...

The Chaderghat police arrested two Malakpet residents, Shaik Sameer and Waseem Khan, for allegedly possessing 20 vials of ...

Natco Pharma launches Semaglutide injection in India for type-2 diabetes, with pricing details and brand names announced.

The company said its Potassium Phosphates Injection is bioequivalent and therapeutically equivalent to the reference listed ...

Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and ...

Elmwood Park (New Jersey) [US], March 16 (ANI): Glenmark Pharmaceuticals Inc USA has announced the upcoming launch of ‘Potassium Phosphates Injection USP’, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P ...

The National Agency for Food and Drug Administration and Control, NAFDAC, has raised an alert over the circulation of ...

Glenmark Pharmaceuticals rose 1.04% to Rs 2,192.50 after its US arm, Glenmark Pharmaceuticals Inc., will launch Potassium Phosphates Injection USP in multiple strengths in the US market.

Glenmark Pharma said the single-dose vial is bioequivalent and therapeutically equivalent to the reference listed drug of the injection in the 45 mM p/15 ml of Hospira Inc.